id	sid	tid	token	lemma	pos
ajird-1393	1	1	american	american	PROPN
ajird-1393	1	2	journal	journal	PROPN
ajird-1393	1	3	of	of	ADP
ajird-1393	1	4	interdisciplinary	interdisciplinary	ADJ
ajird-1393	1	5	research	research	NOUN
ajird-1393	1	6	and	and	CCONJ
ajird-1393	1	7	development	development	NOUN
ajird-1393	1	8	issn	issn	PROPN
ajird-1393	1	9	online	online	NOUN
ajird-1393	1	10	:	:	PUNCT
ajird-1393	1	11	2771	2771	NUM
ajird-1393	1	12	-	-	SYM
ajird-1393	1	13	8948	8948	NUM
ajird-1393	1	14	website	website	NOUN
ajird-1393	1	15	:	:	PUNCT
ajird-1393	1	16	www.ajird.journalspark.org	www.ajird.journalspark.org	ADJ
ajird-1393	1	17	volume	volume	NOUN
ajird-1393	1	18	35	35	NUM
ajird-1393	1	19	,	,	PUNCT
ajird-1393	1	20	december	december	PROPN
ajird-1393	1	21	2024	2024	NUM
ajird-1393	1	22	59	59	NUM
ajird-1393	2	1	|	|	ADV
ajird-1393	2	2	p	p	NOUN
ajird-1393	2	3	a	a	DET
ajird-1393	2	4	g	g	NOUN
ajird-1393	2	5	e	e	ADP
ajird-1393	2	6	systemic	systemic	ADJ
ajird-1393	2	7	effects	effect	NOUN
ajird-1393	2	8	of	of	ADP
ajird-1393	2	9	il-17	il-17	X
ajird-1393	2	10	in	in	ADP
ajird-1393	2	11	reactive	reactive	ADJ
ajird-1393	2	12	arthritis	arthritis	PROPN
ajird-1393	2	13	kh	kh	PROPN
ajird-1393	2	14	.	.	PUNCT
ajird-1393	3	1	s.	s.	PROPN
ajird-1393	3	2	axmedov	axmedov	PROPN
ajird-1393	3	3	,	,	PUNCT
ajird-1393	3	4	dsc	dsc	PROPN
ajird-1393	3	5	,	,	PUNCT
ajird-1393	3	6	professor	professor	PROPN
ajird-1393	3	7	f.	f.	PROPN
ajird-1393	3	8	i.	i.	PROPN
ajird-1393	3	9	khalmetova	khalmetova	PROPN
ajird-1393	3	10	,	,	PUNCT
ajird-1393	3	11	dsc	dsc	NOUN
ajird-1393	3	12	,	,	PUNCT
ajird-1393	3	13	associate	associate	NOUN
ajird-1393	3	14	professor	professor	NOUN
ajird-1393	3	15	,	,	PUNCT
ajird-1393	3	16	i.	i.	PROPN
ajird-1393	3	17	a.	a.	PROPN
ajird-1393	3	18	turayev	turayev	PROPN
ajird-1393	3	19	tashkent	tashkent	PROPN
ajird-1393	3	20	medical	medical	PROPN
ajird-1393	3	21	academy	academy	PROPN
ajird-1393	3	22	abstract	abstract	ADJ
ajird-1393	3	23	treatment	treatment	NOUN
ajird-1393	3	24	of	of	ADP
ajird-1393	3	25	patients	patient	NOUN
ajird-1393	3	26	with	with	ADP
ajird-1393	3	27	reactive	reactive	ADJ
ajird-1393	3	28	arthritis	arthritis	NOUN
ajird-1393	3	29	(	(	PUNCT
ajird-1393	3	30	rea	rea	NOUN
ajird-1393	3	31	)	)	PUNCT
ajird-1393	3	32	remains	remain	VERB
ajird-1393	3	33	one	one	NUM
ajird-1393	3	34	of	of	ADP
ajird-1393	3	35	the	the	DET
ajird-1393	3	36	most	most	ADV
ajird-1393	3	37	difficult	difficult	ADJ
ajird-1393	3	38	problems	problem	NOUN
ajird-1393	3	39	of	of	ADP
ajird-1393	3	40	modern	modern	ADJ
ajird-1393	3	41	rheumatology	rheumatology	NOUN
ajird-1393	3	42	.	.	PUNCT
ajird-1393	4	1	its	its	PRON
ajird-1393	4	2	relevance	relevance	NOUN
ajird-1393	4	3	is	be	AUX
ajird-1393	4	4	due	due	ADJ
ajird-1393	4	5	to	to	ADP
ajird-1393	4	6	the	the	DET
ajird-1393	4	7	progressive	progressive	ADJ
ajird-1393	4	8	course	course	NOUN
ajird-1393	4	9	of	of	ADP
ajird-1393	4	10	the	the	DET
ajird-1393	4	11	disease	disease	NOUN
ajird-1393	4	12	,	,	PUNCT
ajird-1393	4	13	the	the	DET
ajird-1393	4	14	severity	severity	NOUN
ajird-1393	4	15	of	of	ADP
ajird-1393	4	16	the	the	DET
ajird-1393	4	17	lesion	lesion	NOUN
ajird-1393	4	18	of	of	ADP
ajird-1393	4	19	the	the	DET
ajird-1393	4	20	musculoskeletal	musculoskeletal	ADJ
ajird-1393	4	21	system	system	NOUN
ajird-1393	4	22	,	,	PUNCT
ajird-1393	4	23	the	the	DET
ajird-1393	4	24	high	high	ADJ
ajird-1393	4	25	incidence	incidence	NOUN
ajird-1393	4	26	of	of	ADP
ajird-1393	4	27	lesions	lesion	NOUN
ajird-1393	4	28	in	in	ADP
ajird-1393	4	29	people	people	NOUN
ajird-1393	4	30	of	of	ADP
ajird-1393	4	31	working	work	VERB
ajird-1393	4	32	age	age	NOUN
ajird-1393	4	33	,	,	PUNCT
ajird-1393	4	34	the	the	DET
ajird-1393	4	35	early	early	ADJ
ajird-1393	4	36	decline	decline	NOUN
ajird-1393	4	37	in	in	ADP
ajird-1393	4	38	functional	functional	ADJ
ajird-1393	4	39	abilities	ability	NOUN
ajird-1393	4	40	,	,	PUNCT
ajird-1393	4	41	the	the	DET
ajird-1393	4	42	loss	loss	NOUN
ajird-1393	4	43	of	of	ADP
ajird-1393	4	44	professional	professional	ADJ
ajird-1393	4	45	and	and	CCONJ
ajird-1393	4	46	social	social	ADJ
ajird-1393	4	47	skills	skill	NOUN
ajird-1393	4	48	,	,	PUNCT
ajird-1393	4	49	the	the	DET
ajird-1393	4	50	difficulty	difficulty	NOUN
ajird-1393	4	51	of	of	ADP
ajird-1393	4	52	physical	physical	ADJ
ajird-1393	4	53	and	and	CCONJ
ajird-1393	4	54	psychological	psychological	ADJ
ajird-1393	4	55	adaptation	adaptation	NOUN
ajird-1393	4	56	of	of	ADP
ajird-1393	4	57	patients	patient	NOUN
ajird-1393	4	58	to	to	ADP
ajird-1393	4	59	impaired	impaired	ADJ
ajird-1393	4	60	motor	motor	NOUN
ajird-1393	4	61	functions	function	NOUN
ajird-1393	4	62	,	,	PUNCT
ajird-1393	4	63	significant	significant	ADJ
ajird-1393	4	64	disability	disability	NOUN
ajird-1393	4	65	,	,	PUNCT
ajird-1393	4	66	which	which	PRON
ajird-1393	4	67	represent	represent	VERB
ajird-1393	4	68	a	a	DET
ajird-1393	4	69	serious	serious	ADJ
ajird-1393	4	70	general	general	ADJ
ajird-1393	4	71	medical	medical	ADJ
ajird-1393	4	72	and	and	CCONJ
ajird-1393	4	73	social	social	ADJ
ajird-1393	4	74	problem	problem	NOUN
ajird-1393	4	75	,	,	PUNCT
ajird-1393	4	76	leading	lead	VERB
ajird-1393	4	77	to	to	ADP
ajird-1393	4	78	huge	huge	ADJ
ajird-1393	4	79	economic	economic	ADJ
ajird-1393	4	80	losses	loss	NOUN
ajird-1393	4	81	.	.	PUNCT
ajird-1393	5	1	introduction	introduction	NOUN
ajird-1393	5	2	currently	currently	ADV
ajird-1393	5	3	,	,	PUNCT
ajird-1393	5	4	significant	significant	ADJ
ajird-1393	5	5	therapeutic	therapeutic	ADJ
ajird-1393	5	6	progress	progress	NOUN
ajird-1393	5	7	has	have	AUX
ajird-1393	5	8	been	be	AUX
ajird-1393	5	9	made	make	VERB
ajird-1393	5	10	due	due	ADJ
ajird-1393	5	11	to	to	ADP
ajird-1393	5	12	the	the	DET
ajird-1393	5	13	advent	advent	NOUN
ajird-1393	5	14	of	of	ADP
ajird-1393	5	15	biological	biological	ADJ
ajird-1393	5	16	drugs	drug	NOUN
ajird-1393	5	17	,	,	PUNCT
ajird-1393	5	18	which	which	PRON
ajird-1393	5	19	have	have	AUX
ajird-1393	5	20	had	have	VERB
ajird-1393	5	21	a	a	DET
ajird-1393	5	22	huge	huge	ADJ
ajird-1393	5	23	impact	impact	NOUN
ajird-1393	5	24	on	on	ADP
ajird-1393	5	25	the	the	DET
ajird-1393	5	26	effectiveness	effectiveness	NOUN
ajird-1393	5	27	of	of	ADP
ajird-1393	5	28	therapy	therapy	NOUN
ajird-1393	5	29	and	and	CCONJ
ajird-1393	5	30	significantly	significantly	ADV
ajird-1393	5	31	improved	improve	VERB
ajird-1393	5	32	the	the	DET
ajird-1393	5	33	course	course	NOUN
ajird-1393	5	34	of	of	ADP
ajird-1393	5	35	autoimmune	autoimmune	ADJ
ajird-1393	5	36	processes	process	NOUN
ajird-1393	5	37	in	in	ADP
ajird-1393	5	38	many	many	ADJ
ajird-1393	5	39	patients	patient	NOUN
ajird-1393	5	40	with	with	ADP
ajird-1393	5	41	rheumatological	rheumatological	ADJ
ajird-1393	5	42	pathologies	pathology	NOUN
ajird-1393	5	43	.	.	PUNCT
ajird-1393	6	1	according	accord	VERB
ajird-1393	6	2	to	to	ADP
ajird-1393	6	3	the	the	DET
ajird-1393	6	4	literature	literature	NOUN
ajird-1393	6	5	,	,	PUNCT
ajird-1393	6	6	a	a	DET
ajird-1393	6	7	small	small	ADJ
ajird-1393	6	8	number	number	NOUN
ajird-1393	6	9	of	of	ADP
ajird-1393	6	10	observations	observation	NOUN
ajird-1393	6	11	does	do	AUX
ajird-1393	6	12	not	not	PART
ajird-1393	6	13	yet	yet	ADV
ajird-1393	6	14	allow	allow	VERB
ajird-1393	6	15	an	an	DET
ajird-1393	6	16	objective	objective	ADJ
ajird-1393	6	17	assessment	assessment	NOUN
ajird-1393	6	18	of	of	ADP
ajird-1393	6	19	the	the	DET
ajird-1393	6	20	use	use	NOUN
ajird-1393	6	21	of	of	ADP
ajird-1393	6	22	tumor	tumor	NOUN
ajird-1393	6	23	necrosis	necrosis	NOUN
ajird-1393	6	24	factor	factor	NOUN
ajird-1393	6	25	-	-	PUNCT
ajird-1393	6	26	α	α	NOUN
ajird-1393	6	27	inhibitors	inhibitor	NOUN
ajird-1393	6	28	in	in	ADP
ajird-1393	6	29	treatmentresistant	treatmentresistant	ADJ
ajird-1393	6	30	rea	rea	PROPN
ajird-1393	6	31	.	.	PUNCT
ajird-1393	7	1	but	but	CCONJ
ajird-1393	7	2	in	in	ADP
ajird-1393	7	3	the	the	DET
ajird-1393	7	4	clinical	clinical	ADJ
ajird-1393	7	5	case	case	NOUN
ajird-1393	7	6	of	of	ADP
ajird-1393	7	7	tanaka	tanaka	PROPN
ajird-1393	7	8	et	et	PROPN
ajird-1393	7	9	al	al	PROPN
ajird-1393	7	10	.	.	PROPN
ajird-1393	7	11	,	,	PUNCT
ajird-1393	7	12	antibodies	antibodie	VERB
ajird-1393	7	13	to	to	ADP
ajird-1393	7	14	the	the	DET
ajird-1393	7	15	interleukin-6	interleukin-6	NUM
ajird-1393	7	16	receptor	receptor	NOUN
ajird-1393	7	17	were	be	AUX
ajird-1393	7	18	used	use	VERB
ajird-1393	7	19	and	and	CCONJ
ajird-1393	7	20	effectively	effectively	ADV
ajird-1393	7	21	progressed	progress	VERB
ajird-1393	7	22	the	the	DET
ajird-1393	7	23	improvement	improvement	NOUN
ajird-1393	7	24	of	of	ADP
ajird-1393	7	25	the	the	DET
ajird-1393	7	26	symptoms	symptom	NOUN
ajird-1393	7	27	of	of	ADP
ajird-1393	7	28	rea	rea	PROPN
ajird-1393	7	29	,	,	PUNCT
ajird-1393	7	30	which	which	PRON
ajird-1393	7	31	does	do	AUX
ajird-1393	7	32	not	not	PART
ajird-1393	7	33	work	work	VERB
ajird-1393	7	34	on	on	ADP
ajird-1393	7	35	standard	standard	ADJ
ajird-1393	7	36	protocols	protocol	NOUN
ajird-1393	7	37	.	.	PUNCT
ajird-1393	8	1	according	accord	VERB
ajird-1393	8	2	to	to	ADP
ajird-1393	8	3	a	a	DET
ajird-1393	8	4	study	study	NOUN
ajird-1393	8	5	by	by	ADP
ajird-1393	8	6	mens	men	NOUN
ajird-1393	8	7	et	et	PROPN
ajird-1393	8	8	al	al	PROPN
ajird-1393	8	9	.	.	PROPN
ajird-1393	8	10	treatment	treatment	NOUN
ajird-1393	8	11	of	of	ADP
ajird-1393	8	12	rea	rea	PROPN
ajird-1393	8	13	,	,	PUNCT
ajird-1393	8	14	which	which	PRON
ajird-1393	8	15	was	be	AUX
ajird-1393	8	16	complicated	complicate	VERB
ajird-1393	8	17	with	with	ADP
ajird-1393	8	18	spondyloarthritis	spondyloarthritis	NOUN
ajird-1393	8	19	,	,	PUNCT
ajird-1393	8	20	drugs	drug	NOUN
ajird-1393	8	21	with	with	ADP
ajird-1393	8	22	il-17	il-17	NUM
ajird-1393	8	23	inhibitors	inhibitor	NOUN
ajird-1393	8	24	had	have	VERB
ajird-1393	8	25	a	a	DET
ajird-1393	8	26	positive	positive	ADJ
ajird-1393	8	27	effect	effect	NOUN
ajird-1393	8	28	on	on	ADP
ajird-1393	8	29	the	the	DET
ajird-1393	8	30	course	course	NOUN
ajird-1393	8	31	of	of	ADP
ajird-1393	8	32	the	the	DET
ajird-1393	8	33	disease	disease	NOUN
ajird-1393	8	34	.	.	PUNCT
ajird-1393	9	1	the	the	DET
ajird-1393	9	2	aim	aim	NOUN
ajird-1393	9	3	of	of	ADP
ajird-1393	9	4	our	our	PRON
ajird-1393	9	5	study	study	NOUN
ajird-1393	9	6	was	be	AUX
ajird-1393	9	7	to	to	PART
ajird-1393	9	8	investigate	investigate	VERB
ajird-1393	9	9	the	the	DET
ajird-1393	9	10	relationship	relationship	NOUN
ajird-1393	9	11	between	between	ADP
ajird-1393	9	12	the	the	DET
ajird-1393	9	13	g197a	g197a	PROPN
ajird-1393	9	14	polymorphism	polymorphism	NOUN
ajird-1393	9	15	of	of	ADP
ajird-1393	9	16	the	the	DET
ajird-1393	9	17	il	il	PROPN
ajird-1393	9	18	17	17	NUM
ajird-1393	9	19	a	a	DET
ajird-1393	9	20	gene	gene	NOUN
ajird-1393	9	21	and	and	CCONJ
ajird-1393	9	22	the	the	DET
ajird-1393	9	23	presence	presence	NOUN
ajird-1393	9	24	of	of	ADP
ajird-1393	9	25	resistance	resistance	NOUN
ajird-1393	9	26	to	to	PART
ajird-1393	9	27	secukinumab	secukinumab	NOUN
ajird-1393	9	28	in	in	ADP
ajird-1393	9	29	rea	rea	PROPN
ajird-1393	9	30	patients	patient	NOUN
ajird-1393	9	31	with	with	ADP
ajird-1393	9	32	spondyloarthritis	spondyloarthritis	PROPN
ajird-1393	9	33	.	.	PUNCT
ajird-1393	10	1	materials	material	NOUN
ajird-1393	10	2	and	and	CCONJ
ajird-1393	10	3	research	research	NOUN
ajird-1393	10	4	methods	method	NOUN
ajird-1393	10	5	the	the	DET
ajird-1393	10	6	study	study	NOUN
ajird-1393	10	7	was	be	AUX
ajird-1393	10	8	conducted	conduct	VERB
ajird-1393	10	9	in	in	ADP
ajird-1393	10	10	the	the	DET
ajird-1393	10	11	third	third	ADJ
ajird-1393	10	12	city	city	NOUN
ajird-1393	10	13	clinical	clinical	ADJ
ajird-1393	10	14	hospital	hospital	NOUN
ajird-1393	10	15	№	№	ADP
ajird-1393	10	16	3	3	NUM
ajird-1393	10	17	in	in	ADP
ajird-1393	10	18	the	the	DET
ajird-1393	10	19	department	department	NOUN
ajird-1393	10	20	of	of	ADP
ajird-1393	10	21	rheumatology	rheumatology	NOUN
ajird-1393	10	22	of	of	ADP
ajird-1393	10	23	the	the	DET
ajird-1393	10	24	city	city	NOUN
ajird-1393	10	25	of	of	ADP
ajird-1393	10	26	tashkent	tashkent	NOUN
ajird-1393	10	27	.	.	PUNCT
ajird-1393	11	1	the	the	DET
ajird-1393	11	2	study	study	NOUN
ajird-1393	11	3	was	be	AUX
ajird-1393	11	4	conducted	conduct	VERB
ajird-1393	11	5	in	in	ADP
ajird-1393	11	6	76	76	NUM
ajird-1393	11	7	patients	patient	NOUN
ajird-1393	11	8	(	(	PUNCT
ajird-1393	11	9	73	73	NUM
ajird-1393	11	10	women	woman	NOUN
ajird-1393	11	11	,	,	PUNCT
ajird-1393	11	12	3	3	NUM
ajird-1393	11	13	men	man	NOUN
ajird-1393	11	14	,	,	PUNCT
ajird-1393	11	15	24	24	NUM
ajird-1393	11	16	-	-	SYM
ajird-1393	11	17	65	65	NUM
ajird-1393	11	18	years	year	NOUN
ajird-1393	11	19	)	)	PUNCT
ajird-1393	11	20	of	of	ADP
ajird-1393	11	21	rea	rea	PROPN
ajird-1393	11	22	with	with	ADP
ajird-1393	11	23	spondyloarthritis	spondyloarthritis	PROPN
ajird-1393	11	24	.	.	PUNCT
ajird-1393	12	1	the	the	DET
ajird-1393	12	2	control	control	PROPN
ajird-1393	12	3	group	group	NOUN
ajird-1393	12	4	consisted	consist	VERB
ajird-1393	12	5	of	of	ADP
ajird-1393	12	6	24	24	NUM
ajird-1393	12	7	american	american	ADJ
ajird-1393	12	8	journal	journal	PROPN
ajird-1393	12	9	of	of	ADP
ajird-1393	12	10	interdisciplinary	interdisciplinary	ADJ
ajird-1393	12	11	research	research	NOUN
ajird-1393	12	12	and	and	CCONJ
ajird-1393	12	13	development	development	NOUN
ajird-1393	12	14	issn	issn	PROPN
ajird-1393	12	15	online	online	NOUN
ajird-1393	12	16	:	:	PUNCT
ajird-1393	12	17	2771	2771	NUM
ajird-1393	12	18	-	-	SYM
ajird-1393	12	19	8948	8948	NUM
ajird-1393	12	20	website	website	NOUN
ajird-1393	12	21	:	:	PUNCT
ajird-1393	12	22	www.ajird.journalspark.org	www.ajird.journalspark.org	ADJ
ajird-1393	12	23	volume	volume	NOUN
ajird-1393	12	24	35	35	NUM
ajird-1393	12	25	,	,	PUNCT
ajird-1393	12	26	december	december	PROPN
ajird-1393	12	27	2024	2024	NUM
ajird-1393	12	28	60	60	NUM
ajird-1393	12	29	|	|	ADV
ajird-1393	12	30	p	p	X
ajird-1393	12	31	a	a	DET
ajird-1393	12	32	g	g	NOUN
ajird-1393	12	33	e	e	X
ajird-1393	12	34	healthy	healthy	ADJ
ajird-1393	12	35	volunteers	volunteer	NOUN
ajird-1393	12	36	without	without	ADP
ajird-1393	12	37	a	a	DET
ajird-1393	12	38	burdened	burden	VERB
ajird-1393	12	39	rheumatological	rheumatological	ADJ
ajird-1393	12	40	history	history	NOUN
ajird-1393	12	41	.	.	PUNCT
ajird-1393	13	1	rea	rea	PROPN
ajird-1393	13	2	was	be	AUX
ajird-1393	13	3	diagnosed	diagnose	VERB
ajird-1393	13	4	according	accord	VERB
ajird-1393	13	5	to	to	ADP
ajird-1393	13	6	the	the	DET
ajird-1393	13	7	american	american	PROPN
ajird-1393	13	8	college	college	PROPN
ajird-1393	13	9	of	of	ADP
ajird-1393	13	10	rheumatology	rheumatology	NOUN
ajird-1393	13	11	(	(	PUNCT
ajird-1393	13	12	acr	acr	NOUN
ajird-1393	13	13	)	)	PUNCT
ajird-1393	13	14	criteria	criterion	NOUN
ajird-1393	13	15	and	and	CCONJ
ajird-1393	13	16	disease	disease	NOUN
ajird-1393	13	17	activity	activity	NOUN
ajird-1393	13	18	was	be	AUX
ajird-1393	13	19	calculated	calculate	VERB
ajird-1393	13	20	using	use	VERB
ajird-1393	13	21	the	the	DET
ajird-1393	13	22	das28	das28	PROPN
ajird-1393	13	23	calculator	calculator	NOUN
ajird-1393	13	24	.	.	PUNCT
ajird-1393	14	1	all	all	DET
ajird-1393	14	2	patients	patient	NOUN
ajird-1393	14	3	who	who	PRON
ajird-1393	14	4	participated	participate	VERB
ajird-1393	14	5	in	in	ADP
ajird-1393	14	6	our	our	PRON
ajird-1393	14	7	study	study	NOUN
ajird-1393	14	8	were	be	AUX
ajird-1393	14	9	prescribed	prescribe	VERB
ajird-1393	14	10	basic	basic	ADJ
ajird-1393	14	11	therapy	therapy	NOUN
ajird-1393	14	12	with	with	ADP
ajird-1393	14	13	the	the	DET
ajird-1393	14	14	il-17a	il-17a	PROPN
ajird-1393	14	15	inhibitor	inhibitor	NOUN
ajird-1393	14	16	secukinumab	secukinumab	NOUN
ajird-1393	14	17	(	(	PUNCT
ajird-1393	14	18	at	at	ADP
ajird-1393	14	19	a	a	DET
ajird-1393	14	20	dose	dose	NOUN
ajird-1393	14	21	of	of	ADP
ajird-1393	14	22	150	150	NUM
ajird-1393	14	23	mg	mg	NOUN
ajird-1393	14	24	subcutaneously	subcutaneously	ADV
ajird-1393	14	25	)	)	PUNCT
ajird-1393	14	26	and	and	CCONJ
ajird-1393	14	27	the	the	DET
ajird-1393	14	28	patients	patient	NOUN
ajird-1393	14	29	were	be	AUX
ajird-1393	14	30	followed	follow	VERB
ajird-1393	14	31	up	up	ADP
ajird-1393	14	32	for	for	ADP
ajird-1393	14	33	6	6	NUM
ajird-1393	14	34	months	month	NOUN
ajird-1393	14	35	.	.	PUNCT
ajird-1393	15	1	static	static	ADJ
ajird-1393	15	2	processing	processing	NOUN
ajird-1393	15	3	of	of	ADP
ajird-1393	15	4	the	the	DET
ajird-1393	15	5	data	datum	NOUN
ajird-1393	15	6	obtained	obtain	VERB
ajird-1393	15	7	during	during	ADP
ajird-1393	15	8	the	the	DET
ajird-1393	15	9	study	study	NOUN
ajird-1393	15	10	was	be	AUX
ajird-1393	15	11	carried	carry	VERB
ajird-1393	15	12	out	out	ADP
ajird-1393	15	13	using	use	VERB
ajird-1393	15	14	the	the	DET
ajird-1393	15	15	computer	computer	NOUN
ajird-1393	15	16	program	program	NOUN
ajird-1393	15	17	excel	excel	VERB
ajird-1393	15	18	and	and	CCONJ
ajird-1393	15	19	statistica	statistica	PROPN
ajird-1393	15	20	6.0	6.0	NUM
ajird-1393	15	21	.	.	PUNCT
ajird-1393	16	1	to	to	PART
ajird-1393	16	2	identify	identify	VERB
ajird-1393	16	3	the	the	DET
ajird-1393	16	4	correspondence	correspondence	NOUN
ajird-1393	16	5	of	of	ADP
ajird-1393	16	6	genotype	genotype	NOUN
ajird-1393	16	7	distributions	distribution	NOUN
ajird-1393	16	8	to	to	ADP
ajird-1393	16	9	the	the	DET
ajird-1393	16	10	expected	expect	VERB
ajird-1393	16	11	values	value	NOUN
ajird-1393	16	12	at	at	ADP
ajird-1393	16	13	hardy	hardy	ADJ
ajird-1393	16	14	-	-	PUNCT
ajird-1393	16	15	weinberg	weinberg	NOUN
ajird-1393	16	16	equilibrium	equilibrium	NOUN
ajird-1393	16	17	and	and	CCONJ
ajird-1393	16	18	to	to	PART
ajird-1393	16	19	compare	compare	VERB
ajird-1393	16	20	the	the	DET
ajird-1393	16	21	distributions	distribution	NOUN
ajird-1393	16	22	of	of	ADP
ajird-1393	16	23	genotype	genotype	NOUN
ajird-1393	16	24	and	and	CCONJ
ajird-1393	16	25	allele	allele	NOUN
ajird-1393	16	26	frequencies	frequency	NOUN
ajird-1393	16	27	in	in	ADP
ajird-1393	16	28	two	two	NUM
ajird-1393	16	29	subpopulations	subpopulation	NOUN
ajird-1393	16	30	,	,	PUNCT
ajird-1393	16	31	the	the	DET
ajird-1393	16	32	χ2	χ2	PROPN
ajird-1393	16	33	test	test	NOUN
ajird-1393	16	34	(	(	PUNCT
ajird-1393	16	35	pearson	pearson	PROPN
ajird-1393	16	36	)	)	PUNCT
ajird-1393	16	37	was	be	AUX
ajird-1393	16	38	used	use	VERB
ajird-1393	16	39	,	,	PUNCT
ajird-1393	16	40	where	where	SCONJ
ajird-1393	16	41	p<0.05	p<0.05	NOUN
ajird-1393	16	42	was	be	AUX
ajird-1393	16	43	considered	consider	VERB
ajird-1393	16	44	statistically	statistically	ADV
ajird-1393	16	45	significant	significant	ADJ
ajird-1393	16	46	.	.	PUNCT
ajird-1393	17	1	the	the	DET
ajird-1393	17	2	limits	limit	NOUN
ajird-1393	17	3	of	of	ADP
ajird-1393	17	4	the	the	DET
ajird-1393	17	5	95	95	NUM
ajird-1393	17	6	%	%	NOUN
ajird-1393	17	7	confidence	confidence	NOUN
ajird-1393	17	8	interval	interval	NOUN
ajird-1393	17	9	(	(	PUNCT
ajird-1393	17	10	ci	ci	NOUN
ajird-1393	17	11	)	)	PUNCT
ajird-1393	17	12	were	be	AUX
ajird-1393	17	13	calculated	calculate	VERB
ajird-1393	17	14	by	by	ADP
ajird-1393	17	15	the	the	DET
ajird-1393	17	16	method	method	NOUN
ajird-1393	17	17	of	of	ADP
ajird-1393	17	18	b.	b.	PROPN
ajird-1393	17	19	woolf	woolf	PROPN
ajird-1393	17	20	.	.	PUNCT
ajird-1393	18	1	genomic	genomic	PROPN
ajird-1393	18	2	dna	dna	PROPN
ajird-1393	18	3	was	be	AUX
ajird-1393	18	4	extracted	extract	VERB
ajird-1393	18	5	from	from	ADP
ajird-1393	18	6	whole	whole	ADJ
ajird-1393	18	7	blood	blood	NOUN
ajird-1393	18	8	collected	collect	VERB
ajird-1393	18	9	in	in	ADP
ajird-1393	18	10	edta	edta	NOUN
ajird-1393	18	11	tubes	tube	NOUN
ajird-1393	18	12	using	use	VERB
ajird-1393	18	13	the	the	DET
ajird-1393	18	14	genematrix	genematrix	NOUN
ajird-1393	18	15	quick	quick	ADJ
ajird-1393	18	16	blood	blood	NOUN
ajird-1393	18	17	dna	dna	NOUN
ajird-1393	18	18	purification	purification	NOUN
ajird-1393	18	19	kit	kit	NOUN
ajird-1393	18	20	(	(	PUNCT
ajird-1393	18	21	poland	poland	PROPN
ajird-1393	18	22	)	)	PUNCT
ajird-1393	18	23	.	.	PUNCT
ajird-1393	19	1	identification	identification	NOUN
ajird-1393	19	2	of	of	ADP
ajird-1393	19	3	all	all	DET
ajird-1393	19	4	studied	studied	ADJ
ajird-1393	19	5	polymorphisms	polymorphism	NOUN
ajird-1393	19	6	in	in	ADP
ajird-1393	19	7	the	the	DET
ajird-1393	19	8	il17a	il17a	NOUN
ajird-1393	19	9	gene	gene	NOUN
ajird-1393	19	10	was	be	AUX
ajird-1393	19	11	performed	perform	VERB
ajird-1393	19	12	using	use	VERB
ajird-1393	19	13	the	the	DET
ajird-1393	19	14	taqmannsnp	taqmannsnp	NOUN
ajird-1393	19	15	genotyping	genotype	VERB
ajird-1393	19	16	test	test	NOUN
ajird-1393	19	17	:	:	PUNCT
ajird-1393	19	18	17a	17a	PROPN
ajird-1393	19	19	(	(	PUNCT
ajird-1393	19	20	il-17a	il-17a	PROPN
ajird-1393	19	21	g-197a	g-197a	PROPN
ajird-1393	19	22	)	)	PUNCT
ajird-1393	19	23	.	.	PUNCT
ajird-1393	20	1	the	the	DET
ajird-1393	20	2	reaction	reaction	NOUN
ajird-1393	20	3	was	be	AUX
ajird-1393	20	4	carried	carry	VERB
ajird-1393	20	5	out	out	ADP
ajird-1393	20	6	in	in	ADP
ajird-1393	20	7	duplicate	duplicate	NOUN
ajird-1393	20	8	using	use	VERB
ajird-1393	20	9	the	the	DET
ajird-1393	20	10	fast	fast	ADJ
ajird-1393	20	11	real	real	ADJ
ajird-1393	20	12	-	-	PUNCT
ajird-1393	20	13	time	time	NOUN
ajird-1393	20	14	pcr	pcr	ADJ
ajird-1393	20	15	detection	detection	NOUN
ajird-1393	20	16	system	system	NOUN
ajird-1393	20	17	(	(	PUNCT
ajird-1393	20	18	germany	germany	PROPN
ajird-1393	20	19	)	)	PUNCT
ajird-1393	20	20	.	.	PUNCT
ajird-1393	21	1	results	result	NOUN
ajird-1393	21	2	and	and	CCONJ
ajird-1393	21	3	discussion	discussion	NOUN
ajird-1393	21	4	in	in	ADP
ajird-1393	21	5	our	our	PRON
ajird-1393	21	6	study	study	NOUN
ajird-1393	21	7	,	,	PUNCT
ajird-1393	21	8	76	76	NUM
ajird-1393	21	9	patients	patient	NOUN
ajird-1393	21	10	with	with	ADP
ajird-1393	21	11	rea	rea	PROPN
ajird-1393	21	12	and	and	CCONJ
ajird-1393	21	13	24	24	NUM
ajird-1393	21	14	healthy	healthy	ADJ
ajird-1393	21	15	volunteers	volunteer	NOUN
ajird-1393	21	16	without	without	ADP
ajird-1393	21	17	a	a	DET
ajird-1393	21	18	rheumatological	rheumatological	ADJ
ajird-1393	21	19	history	history	NOUN
ajird-1393	21	20	were	be	AUX
ajird-1393	21	21	studied	study	VERB
ajird-1393	21	22	.	.	PUNCT
ajird-1393	22	1	all	all	DET
ajird-1393	22	2	patients	patient	NOUN
ajird-1393	22	3	underwent	undergo	VERB
ajird-1393	22	4	genotyping	genotyping	NOUN
ajird-1393	22	5	of	of	ADP
ajird-1393	22	6	the	the	DET
ajird-1393	22	7	g197a	g197a	PROPN
ajird-1393	22	8	polymorphism	polymorphism	NOUN
ajird-1393	22	9	of	of	ADP
ajird-1393	22	10	the	the	DET
ajird-1393	22	11	il	il	PROPN
ajird-1393	22	12	17a	17a	PROPN
ajird-1393	22	13	gene	gene	PROPN
ajird-1393	22	14	.	.	PUNCT
ajird-1393	23	1	the	the	DET
ajird-1393	23	2	results	result	NOUN
ajird-1393	23	3	of	of	ADP
ajird-1393	23	4	genotyping	genotyping	NOUN
ajird-1393	23	5	are	be	AUX
ajird-1393	23	6	shown	show	VERB
ajird-1393	23	7	in	in	ADP
ajird-1393	23	8	picture	picture	NOUN
ajird-1393	23	9	№	№	ADP
ajird-1393	23	10	1	1	NUM
ajird-1393	23	11	.	.	PUNCT
ajird-1393	24	1	picture	picture	NOUN
ajird-1393	24	2	№	№	NUM
ajird-1393	24	3	1	1	NUM
ajird-1393	24	4	percentage	percentage	NOUN
ajird-1393	24	5	distribution	distribution	NOUN
ajird-1393	24	6	of	of	ADP
ajird-1393	24	7	genotypes	genotype	NOUN
ajird-1393	24	8	of	of	ADP
ajird-1393	24	9	g197a	g197a	PROPN
ajird-1393	24	10	polymorphism	polymorphism	NOUN
ajird-1393	24	11	of	of	ADP
ajird-1393	24	12	the	the	DET
ajird-1393	24	13	il	il	PROPN
ajird-1393	24	14	17a	17a	PROPN
ajird-1393	24	15	gene	gene	VERB
ajird-1393	24	16	in	in	ADP
ajird-1393	24	17	rea	rea	PROPN
ajird-1393	24	18	patients	patient	NOUN
ajird-1393	24	19	with	with	ADP
ajird-1393	24	20	spondyloarthritis	spondyloarthritis	NOUN
ajird-1393	24	21	and	and	CCONJ
ajird-1393	24	22	in	in	ADP
ajird-1393	24	23	the	the	DET
ajird-1393	24	24	control	control	NOUN
ajird-1393	24	25	group	group	NOUN
ajird-1393	24	26	as	as	SCONJ
ajird-1393	24	27	can	can	AUX
ajird-1393	24	28	be	be	AUX
ajird-1393	24	29	seen	see	VERB
ajird-1393	24	30	from	from	ADP
ajird-1393	24	31	picture	picture	NOUN
ajird-1393	24	32	№	№	ADP
ajird-1393	24	33	1	1	NUM
ajird-1393	24	34	,	,	PUNCT
ajird-1393	24	35	the	the	DET
ajird-1393	24	36	gg	gg	NOUN
ajird-1393	24	37	genotype	genotype	NOUN
ajird-1393	24	38	of	of	ADP
ajird-1393	24	39	the	the	DET
ajird-1393	24	40	g197a	g197a	PROPN
ajird-1393	24	41	gene	gene	NOUN
ajird-1393	24	42	was	be	AUX
ajird-1393	24	43	found	find	VERB
ajird-1393	24	44	in	in	ADP
ajird-1393	24	45	31.5	31.5	NUM
ajird-1393	24	46	%	%	NOUN
ajird-1393	24	47	of	of	ADP
ajird-1393	24	48	rea	rea	NOUN
ajird-1393	24	49	patients	patient	NOUN
ajird-1393	24	50	,	,	PUNCT
ajird-1393	24	51	while	while	SCONJ
ajird-1393	24	52	in	in	ADP
ajird-1393	24	53	the	the	DET
ajird-1393	24	54	control	control	NOUN
ajird-1393	24	55	group	group	NOUN
ajird-1393	24	56	it	it	PRON
ajird-1393	24	57	was	be	AUX
ajird-1393	24	58	found	find	VERB
ajird-1393	24	59	in	in	ADP
ajird-1393	24	60	20.8	20.8	NUM
ajird-1393	24	61	%	%	NOUN
ajird-1393	24	62	of	of	ADP
ajird-1393	24	63	cases	case	NOUN
ajird-1393	24	64	.	.	PUNCT
ajird-1393	25	1	the	the	DET
ajird-1393	25	2	ct	ct	PROPN
ajird-1393	25	3	genotype	genotype	NOUN
ajird-1393	25	4	was	be	AUX
ajird-1393	25	5	found	find	VERB
ajird-1393	25	6	in	in	ADP
ajird-1393	25	7	39.5	39.5	NUM
ajird-1393	25	8	%	%	NOUN
ajird-1393	25	9	of	of	ADP
ajird-1393	25	10	patients	patient	NOUN
ajird-1393	25	11	,	,	PUNCT
ajird-1393	25	12	and	and	CCONJ
ajird-1393	25	13	in	in	ADP
ajird-1393	25	14	the	the	DET
ajird-1393	25	15	control	control	NOUN
ajird-1393	25	16	group	group	NOUN
ajird-1393	25	17	it	it	PRON
ajird-1393	25	18	was	be	AUX
ajird-1393	25	19	significantly	significantly	ADV
ajird-1393	25	20	higher	high	ADJ
ajird-1393	25	21	and	and	CCONJ
ajird-1393	25	22	20,8	20,8	NUM
ajird-1393	25	23	%	%	NOUN
ajird-1393	26	1	31,5	31,5	NUM
ajird-1393	26	2	%	%	NOUN
ajird-1393	26	3	62,5	62,5	NUM
ajird-1393	26	4	%	%	NOUN
ajird-1393	26	5	39,5	39,5	NUM
ajird-1393	26	6	%	%	NOUN
ajird-1393	26	7	16,6	16,6	NUM
ajird-1393	26	8	%	%	NOUN
ajird-1393	26	9	29.0	29.0	NUM
ajird-1393	26	10	%	%	NOUN
ajird-1393	26	11	0	0	NUM
ajird-1393	26	12	10	10	NUM
ajird-1393	26	13	20	20	NUM
ajird-1393	26	14	30	30	NUM
ajird-1393	26	15	40	40	NUM
ajird-1393	26	16	50	50	NUM
ajird-1393	26	17	60	60	NUM
ajird-1393	26	18	70	70	NUM
ajird-1393	26	19	80	80	NUM
ajird-1393	26	20	90	90	NUM
ajird-1393	26	21	100	100	NUM
ajird-1393	26	22	control	control	NOUN
ajird-1393	26	23	group	group	NOUN
ajird-1393	26	24	patients	patient	NOUN
ajird-1393	26	25	with	with	ADP
ajird-1393	26	26	rea	rea	PROPN
ajird-1393	26	27	gg	gg	PROPN
ajird-1393	26	28	genotype	genotype	PROPN
ajird-1393	26	29	ga	ga	PROPN
ajird-1393	26	30	genotype	genotype	NOUN
ajird-1393	26	31	aa	aa	PROPN
ajird-1393	26	32	genotype	genotype	PROPN
ajird-1393	26	33	american	american	PROPN
ajird-1393	26	34	journal	journal	PROPN
ajird-1393	26	35	of	of	ADP
ajird-1393	26	36	interdisciplinary	interdisciplinary	ADJ
ajird-1393	26	37	research	research	NOUN
ajird-1393	26	38	and	and	CCONJ
ajird-1393	26	39	development	development	NOUN
ajird-1393	26	40	issn	issn	PROPN
ajird-1393	26	41	online	online	NOUN
ajird-1393	26	42	:	:	PUNCT
ajird-1393	26	43	2771	2771	NUM
ajird-1393	26	44	-	-	SYM
ajird-1393	26	45	8948	8948	NUM
ajird-1393	26	46	website	website	NOUN
ajird-1393	26	47	:	:	PUNCT
ajird-1393	26	48	www.ajird.journalspark.org	www.ajird.journalspark.org	ADJ
ajird-1393	26	49	volume	volume	NOUN
ajird-1393	26	50	35	35	NUM
ajird-1393	26	51	,	,	PUNCT
ajird-1393	26	52	december	december	PROPN
ajird-1393	26	53	2024	2024	NUM
ajird-1393	26	54	61	61	NUM
ajird-1393	27	1	|	|	ADV
ajird-1393	27	2	p	p	NOUN
ajird-1393	27	3	a	a	DET
ajird-1393	27	4	g	g	NOUN
ajird-1393	27	5	e	e	NOUN
ajird-1393	27	6	amounted	amount	VERB
ajird-1393	27	7	to	to	ADP
ajird-1393	27	8	62.5	62.5	NUM
ajird-1393	27	9	%	%	NOUN
ajird-1393	27	10	of	of	ADP
ajird-1393	27	11	cases	case	NOUN
ajird-1393	27	12	.	.	PUNCT
ajird-1393	28	1	the	the	DET
ajird-1393	28	2	frequency	frequency	NOUN
ajird-1393	28	3	of	of	ADP
ajird-1393	28	4	occurrence	occurrence	NOUN
ajird-1393	28	5	of	of	ADP
ajird-1393	28	6	the	the	DET
ajird-1393	28	7	mutant	mutant	NOUN
ajird-1393	28	8	tt	tt	PROPN
ajird-1393	28	9	genotype	genotype	NOUN
ajird-1393	28	10	was	be	AUX
ajird-1393	28	11	29.0	29.0	NUM
ajird-1393	28	12	%	%	NOUN
ajird-1393	28	13	and	and	CCONJ
ajird-1393	28	14	16.6	16.6	NUM
ajird-1393	28	15	%	%	NOUN
ajird-1393	28	16	in	in	ADP
ajird-1393	28	17	the	the	DET
ajird-1393	28	18	control	control	NOUN
ajird-1393	28	19	group	group	NOUN
ajird-1393	28	20	.	.	PUNCT
ajird-1393	29	1	picture	picture	NOUN
ajird-1393	29	2	№	№	NUM
ajird-1393	29	3	2	2	NUM
ajird-1393	29	4	distribution	distribution	NOUN
ajird-1393	29	5	of	of	ADP
ajird-1393	29	6	alleles	allele	NOUN
ajird-1393	29	7	of	of	ADP
ajird-1393	29	8	polymorphism	polymorphism	NOUN
ajird-1393	29	9	g197a	g197a	PROPN
ajird-1393	29	10	il	il	PROPN
ajird-1393	29	11	17a	17a	PROPN
ajird-1393	29	12	gene	gene	VERB
ajird-1393	29	13	as	as	SCONJ
ajird-1393	29	14	can	can	AUX
ajird-1393	29	15	be	be	AUX
ajird-1393	29	16	seen	see	VERB
ajird-1393	29	17	from	from	ADP
ajird-1393	29	18	picture	picture	NOUN
ajird-1393	29	19	№	№	ADP
ajird-1393	29	20	2	2	NUM
ajird-1393	29	21	the	the	DET
ajird-1393	29	22	percentages	percentage	NOUN
ajird-1393	29	23	of	of	ADP
ajird-1393	29	24	the	the	DET
ajird-1393	29	25	g	g	NOUN
ajird-1393	29	26	and	and	CCONJ
ajird-1393	29	27	a	a	DET
ajird-1393	29	28	alleles	allele	NOUN
ajird-1393	29	29	were	be	AUX
ajird-1393	29	30	almost	almost	ADV
ajird-1393	29	31	the	the	DET
ajird-1393	29	32	same	same	ADJ
ajird-1393	29	33	.	.	PUNCT
ajird-1393	30	1	the	the	DET
ajird-1393	30	2	g	g	PROPN
ajird-1393	30	3	allele	allele	NOUN
ajird-1393	30	4	of	of	ADP
ajird-1393	30	5	the	the	DET
ajird-1393	30	6	g197a	g197a	PROPN
ajird-1393	30	7	isoform	isoform	NOUN
ajird-1393	30	8	was	be	AUX
ajird-1393	30	9	found	find	VERB
ajird-1393	30	10	in	in	ADP
ajird-1393	30	11	51.3	51.3	NUM
ajird-1393	30	12	%	%	NOUN
ajird-1393	30	13	,	,	PUNCT
ajird-1393	30	14	the	the	DET
ajird-1393	30	15	a	a	DET
ajird-1393	30	16	allele	allele	NOUN
ajird-1393	30	17	was	be	AUX
ajird-1393	30	18	found	find	VERB
ajird-1393	30	19	in	in	ADP
ajird-1393	30	20	48.7	48.7	NUM
ajird-1393	30	21	%	%	NOUN
ajird-1393	30	22	of	of	ADP
ajird-1393	30	23	rea	rea	PROPN
ajird-1393	30	24	patients	patient	NOUN
ajird-1393	30	25	.	.	PUNCT
ajird-1393	31	1	based	base	VERB
ajird-1393	31	2	on	on	ADP
ajird-1393	31	3	the	the	DET
ajird-1393	31	4	carriage	carriage	NOUN
ajird-1393	31	5	of	of	ADP
ajird-1393	31	6	three	three	NUM
ajird-1393	31	7	genotypic	genotypic	ADJ
ajird-1393	31	8	variants	variant	NOUN
ajird-1393	31	9	of	of	ADP
ajird-1393	31	10	the	the	DET
ajird-1393	31	11	g197a	g197a	PROPN
ajird-1393	31	12	il	il	PROPN
ajird-1393	31	13	17a	17a	PROPN
ajird-1393	31	14	gene	gene	NOUN
ajird-1393	31	15	polymorphism	polymorphism	NOUN
ajird-1393	31	16	,	,	PUNCT
ajird-1393	31	17	the	the	DET
ajird-1393	31	18	following	follow	VERB
ajird-1393	31	19	associated	associated	ADJ
ajird-1393	31	20	phenotypic	phenotypic	ADJ
ajird-1393	31	21	groups	group	NOUN
ajird-1393	31	22	were	be	AUX
ajird-1393	31	23	identified	identify	VERB
ajird-1393	31	24	depending	depend	VERB
ajird-1393	31	25	on	on	ADP
ajird-1393	31	26	the	the	DET
ajird-1393	31	27	response	response	NOUN
ajird-1393	31	28	to	to	PART
ajird-1393	31	29	secukinumab	secukinumab	VERB
ajird-1393	31	30	treatment	treatment	NOUN
ajird-1393	31	31	(	(	PUNCT
ajird-1393	31	32	picture	picture	NOUN
ajird-1393	31	33	№	№	ADP
ajird-1393	31	34	3	3	NUM
ajird-1393	31	35	)	)	PUNCT
ajird-1393	31	36	.	.	PUNCT
ajird-1393	32	1	“	"	PUNCT
ajird-1393	32	2	good	good	ADJ
ajird-1393	32	3	”	"	PUNCT
ajird-1393	32	4	response	response	NOUN
ajird-1393	32	5	to	to	ADP
ajird-1393	32	6	secukinumab	secukinumab	NOUN
ajird-1393	32	7	(	(	PUNCT
ajird-1393	32	8	29.5	29.5	NUM
ajird-1393	32	9	%	%	NOUN
ajird-1393	32	10	)	)	PUNCT
ajird-1393	32	11	carriers	carrier	NOUN
ajird-1393	32	12	of	of	ADP
ajird-1393	32	13	the	the	DET
ajird-1393	32	14	aa	aa	PROPN
ajird-1393	32	15	mutant	mutant	ADJ
ajird-1393	32	16	genotype	genotype	NOUN
ajird-1393	32	17	were	be	AUX
ajird-1393	32	18	phenotypically	phenotypically	ADV
ajird-1393	32	19	characterized	characterize	VERB
ajird-1393	32	20	by	by	ADP
ajird-1393	32	21	a	a	DET
ajird-1393	32	22	good	good	ADJ
ajird-1393	32	23	clinical	clinical	ADJ
ajird-1393	32	24	response	response	NOUN
ajird-1393	32	25	(	(	PUNCT
ajird-1393	32	26	das<2.6	das<2.6	PROPN
ajird-1393	32	27	3	3	NUM
ajird-1393	32	28	-	-	SYM
ajird-1393	32	29	6	6	NUM
ajird-1393	32	30	months	month	NOUN
ajird-1393	32	31	)	)	PUNCT
ajird-1393	32	32	to	to	PART
ajird-1393	32	33	secukinumab	secukinumab	VERB
ajird-1393	32	34	treatment	treatment	NOUN
ajird-1393	32	35	,	,	PUNCT
ajird-1393	32	36	as	as	ADV
ajird-1393	32	37	well	well	ADV
ajird-1393	32	38	as	as	ADP
ajird-1393	32	39	low	low	ADJ
ajird-1393	32	40	disease	disease	NOUN
ajird-1393	32	41	activity	activity	NOUN
ajird-1393	32	42	.	.	PUNCT
ajird-1393	33	1	“	"	PUNCT
ajird-1393	33	2	poor	poor	ADJ
ajird-1393	33	3	”	"	PUNCT
ajird-1393	33	4	response	response	NOUN
ajird-1393	33	5	to	to	ADP
ajird-1393	33	6	secukinumab	secukinumab	NOUN
ajird-1393	33	7	(	(	PUNCT
ajird-1393	33	8	31.5	31.5	NUM
ajird-1393	33	9	%	%	NOUN
ajird-1393	33	10	)	)	PUNCT
ajird-1393	33	11	,	,	PUNCT
ajird-1393	33	12	carriers	carrier	NOUN
ajird-1393	33	13	of	of	ADP
ajird-1393	33	14	the	the	DET
ajird-1393	33	15	gg	gg	NOUN
ajird-1393	33	16	genotype	genotype	NOUN
ajird-1393	33	17	were	be	AUX
ajird-1393	33	18	characterized	characterize	VERB
ajird-1393	33	19	by	by	ADP
ajird-1393	33	20	high	high	ADJ
ajird-1393	33	21	disease	disease	NOUN
ajird-1393	33	22	activity	activity	NOUN
ajird-1393	33	23	and	and	CCONJ
ajird-1393	33	24	clinically	clinically	ADV
ajird-1393	33	25	poor	poor	ADJ
ajird-1393	33	26	drug	drug	NOUN
ajird-1393	33	27	response	response	NOUN
ajird-1393	33	28	(	(	PUNCT
ajird-1393	33	29	das>2.6	das>2.6	PROPN
ajird-1393	33	30	)	)	PUNCT
ajird-1393	33	31	to	to	PART
ajird-1393	33	32	secukinumab	secukinumab	VERB
ajird-1393	33	33	treatment	treatment	NOUN
ajird-1393	33	34	(	(	PUNCT
ajird-1393	33	35	picture	picture	NOUN
ajird-1393	33	36	№	№	ADP
ajird-1393	33	37	3	3	NUM
ajird-1393	33	38	)	)	PUNCT
ajird-1393	33	39	.	.	PUNCT
ajird-1393	34	1	the	the	DET
ajird-1393	34	2	“	"	PUNCT
ajird-1393	34	3	moderate	moderate	ADJ
ajird-1393	34	4	”	"	PUNCT
ajird-1393	34	5	response	response	NOUN
ajird-1393	34	6	(	(	PUNCT
ajird-1393	34	7	39.5	39.5	NUM
ajird-1393	34	8	%	%	NOUN
ajird-1393	34	9	)	)	PUNCT
ajird-1393	34	10	carriers	carrier	NOUN
ajird-1393	34	11	of	of	ADP
ajird-1393	34	12	the	the	DET
ajird-1393	34	13	heterozygous	heterozygous	ADJ
ajird-1393	34	14	ga	ga	NOUN
ajird-1393	34	15	genotype	genotype	NOUN
ajird-1393	34	16	phenotypically	phenotypically	ADV
ajird-1393	34	17	showed	show	VERB
ajird-1393	34	18	an	an	DET
ajird-1393	34	19	average	average	ADJ
ajird-1393	34	20	clinical	clinical	ADJ
ajird-1393	34	21	response	response	NOUN
ajird-1393	34	22	(	(	PUNCT
ajird-1393	34	23	das<2.6	das<2.6	PROPN
ajird-1393	34	24	less	less	ADJ
ajird-1393	34	25	than	than	ADP
ajird-1393	34	26	3	3	NUM
ajird-1393	34	27	months	month	NOUN
ajird-1393	34	28	)	)	PUNCT
ajird-1393	34	29	to	to	PART
ajird-1393	34	30	secukinumab	secukinumab	VERB
ajird-1393	34	31	treatment	treatment	NOUN
ajird-1393	34	32	and	and	CCONJ
ajird-1393	34	33	lower	low	ADJ
ajird-1393	34	34	disease	disease	NOUN
ajird-1393	34	35	activity	activity	NOUN
ajird-1393	34	36	compared	compare	VERB
ajird-1393	34	37	to	to	ADP
ajird-1393	34	38	the	the	DET
ajird-1393	34	39	“	"	PUNCT
ajird-1393	34	40	poor	poor	ADJ
ajird-1393	34	41	response	response	NOUN
ajird-1393	34	42	”	"	PUNCT
ajird-1393	34	43	group	group	NOUN
ajird-1393	34	44	.	.	PUNCT
ajird-1393	35	1	picture	picture	NOUN
ajird-1393	35	2	№	№	NUM
ajird-1393	35	3	3	3	NUM
ajird-1393	35	4	percentage	percentage	NOUN
ajird-1393	35	5	distribution	distribution	NOUN
ajird-1393	35	6	of	of	ADP
ajird-1393	35	7	rea	rea	NOUN
ajird-1393	35	8	patients	patient	NOUN
ajird-1393	35	9	by	by	ADP
ajird-1393	35	10	medication	medication	NOUN
ajird-1393	35	11	response	response	NOUN
ajird-1393	35	12	to	to	PART
ajird-1393	35	13	secukinumab	secukinumab	VERB
ajird-1393	35	14	treatment	treatment	NOUN
ajird-1393	35	15	51.3	51.3	NUM
ajird-1393	35	16	48.7	48.7	NUM
ajird-1393	35	17	0	0	NUM
ajird-1393	35	18	10	10	NUM
ajird-1393	35	19	20	20	NUM
ajird-1393	35	20	30	30	NUM
ajird-1393	35	21	40	40	NUM
ajird-1393	35	22	50	50	NUM
ajird-1393	35	23	60	60	NUM
ajird-1393	35	24	70	70	NUM
ajird-1393	35	25	allel	allel	NOUN
ajird-1393	35	26	g	g	PROPN
ajird-1393	35	27	allel	allel	NOUN
ajird-1393	35	28	a	a	DET
ajird-1393	35	29	31,5	31,5	NUM
ajird-1393	35	30	%	%	NOUN
ajird-1393	35	31	39,5	39,5	NUM
ajird-1393	35	32	%	%	NOUN
ajird-1393	35	33	29,0	29,0	NUM
ajird-1393	35	34	%	%	NOUN
ajird-1393	35	35	“	"	PUNCT
ajird-1393	35	36	good	good	ADJ
ajird-1393	35	37	”	"	PUNCT
ajird-1393	35	38	response	response	NOUN
ajird-1393	35	39	“	"	PUNCT
ajird-1393	35	40	moderate	moderate	ADJ
ajird-1393	35	41	”	"	PUNCT
ajird-1393	35	42	response	response	NOUN
ajird-1393	35	43	“	"	PUNCT
ajird-1393	35	44	poor	poor	ADJ
ajird-1393	35	45	"	"	PUNCT
ajird-1393	35	46	response	response	NOUN
ajird-1393	35	47	american	american	PROPN
ajird-1393	35	48	journal	journal	PROPN
ajird-1393	35	49	of	of	ADP
ajird-1393	35	50	interdisciplinary	interdisciplinary	ADJ
ajird-1393	35	51	research	research	NOUN
ajird-1393	35	52	and	and	CCONJ
ajird-1393	35	53	development	development	NOUN
ajird-1393	35	54	issn	issn	PROPN
ajird-1393	35	55	online	online	NOUN
ajird-1393	35	56	:	:	PUNCT
ajird-1393	35	57	2771	2771	NUM
ajird-1393	35	58	-	-	SYM
ajird-1393	35	59	8948	8948	NUM
ajird-1393	35	60	website	website	NOUN
ajird-1393	35	61	:	:	PUNCT
ajird-1393	35	62	www.ajird.journalspark.org	www.ajird.journalspark.org	ADJ
ajird-1393	35	63	volume	volume	NOUN
ajird-1393	35	64	35	35	NUM
ajird-1393	35	65	,	,	PUNCT
ajird-1393	35	66	december	december	PROPN
ajird-1393	35	67	2024	2024	NUM
ajird-1393	35	68	62	62	NUM
ajird-1393	36	1	|	|	ADV
ajird-1393	36	2	p	p	NOUN
ajird-1393	36	3	a	a	DET
ajird-1393	36	4	g	g	NOUN
ajird-1393	36	5	e	e	NOUN
ajird-1393	36	6	despite	despite	SCONJ
ajird-1393	36	7	the	the	DET
ajird-1393	36	8	large	large	ADJ
ajird-1393	36	9	number	number	NOUN
ajird-1393	36	10	of	of	ADP
ajird-1393	36	11	studies	study	NOUN
ajird-1393	36	12	devoted	devote	VERB
ajird-1393	36	13	to	to	ADP
ajird-1393	36	14	the	the	DET
ajird-1393	36	15	study	study	NOUN
ajird-1393	36	16	of	of	ADP
ajird-1393	36	17	polymorphism	polymorphism	NOUN
ajird-1393	36	18	of	of	ADP
ajird-1393	36	19	the	the	DET
ajird-1393	36	20	il	il	PROPN
ajird-1393	36	21	17a	17a	PROPN
ajird-1393	36	22	gene	gene	PROPN
ajird-1393	36	23	,	,	PUNCT
ajird-1393	36	24	the	the	DET
ajird-1393	36	25	results	result	NOUN
ajird-1393	36	26	remain	remain	VERB
ajird-1393	36	27	contradictory	contradictory	ADJ
ajird-1393	36	28	,	,	PUNCT
ajird-1393	36	29	which	which	PRON
ajird-1393	36	30	aroused	arouse	VERB
ajird-1393	36	31	our	our	PRON
ajird-1393	36	32	interest	interest	NOUN
ajird-1393	36	33	.	.	PUNCT
ajird-1393	37	1	according	accord	VERB
ajird-1393	37	2	to	to	ADP
ajird-1393	37	3	our	our	PRON
ajird-1393	37	4	data	datum	NOUN
ajird-1393	37	5	,	,	PUNCT
ajird-1393	37	6	there	there	PRON
ajird-1393	37	7	were	be	VERB
ajird-1393	37	8	no	no	DET
ajird-1393	37	9	significant	significant	ADJ
ajird-1393	37	10	differences	difference	NOUN
ajird-1393	37	11	in	in	ADP
ajird-1393	37	12	the	the	DET
ajird-1393	37	13	distribution	distribution	NOUN
ajird-1393	37	14	of	of	ADP
ajird-1393	37	15	alleles	allele	NOUN
ajird-1393	37	16	of	of	ADP
ajird-1393	37	17	the	the	DET
ajird-1393	37	18	g197a	g197a	PROPN
ajird-1393	37	19	polymorphism	polymorphism	NOUN
ajird-1393	37	20	of	of	ADP
ajird-1393	37	21	the	the	DET
ajird-1393	37	22	il	il	PROPN
ajird-1393	37	23	17a	17a	PROPN
ajird-1393	37	24	gene	gene	VERB
ajird-1393	37	25	in	in	ADP
ajird-1393	37	26	rea	rea	PROPN
ajird-1393	37	27	patients	patient	NOUN
ajird-1393	37	28	and	and	CCONJ
ajird-1393	37	29	healthy	healthy	ADJ
ajird-1393	37	30	controls	control	NOUN
ajird-1393	37	31	.	.	PUNCT
ajird-1393	38	1	but	but	CCONJ
ajird-1393	38	2	when	when	SCONJ
ajird-1393	38	3	comparing	compare	VERB
ajird-1393	38	4	genotypic	genotypic	ADJ
ajird-1393	38	5	variants	variant	NOUN
ajird-1393	38	6	,	,	PUNCT
ajird-1393	38	7	we	we	PRON
ajird-1393	38	8	revealed	reveal	VERB
ajird-1393	38	9	differences	difference	NOUN
ajird-1393	38	10	:	:	PUNCT
ajird-1393	38	11	healthy	healthy	ADJ
ajird-1393	38	12	gg	gg	NOUN
ajird-1393	38	13	and	and	CCONJ
ajird-1393	38	14	mutant	mutant	ADJ
ajird-1393	38	15	aa	aa	NOUN
ajird-1393	38	16	genotypes	genotype	NOUN
ajird-1393	38	17	were	be	AUX
ajird-1393	38	18	more	more	ADV
ajird-1393	38	19	common	common	ADJ
ajird-1393	38	20	in	in	ADP
ajird-1393	38	21	patients	patient	NOUN
ajird-1393	38	22	,	,	PUNCT
ajird-1393	38	23	while	while	SCONJ
ajird-1393	38	24	the	the	DET
ajird-1393	38	25	heterozygous	heterozygous	ADJ
ajird-1393	38	26	ga	ga	NOUN
ajird-1393	38	27	genotype	genotype	NOUN
ajird-1393	38	28	was	be	AUX
ajird-1393	38	29	more	more	ADV
ajird-1393	38	30	common	common	ADJ
ajird-1393	38	31	in	in	ADP
ajird-1393	38	32	healthy	healthy	ADJ
ajird-1393	38	33	people	people	NOUN
ajird-1393	38	34	.	.	PUNCT
ajird-1393	39	1	based	base	VERB
ajird-1393	39	2	on	on	ADP
ajird-1393	39	3	the	the	DET
ajird-1393	39	4	results	result	NOUN
ajird-1393	39	5	of	of	ADP
ajird-1393	39	6	genotyping	genotyping	NOUN
ajird-1393	39	7	,	,	PUNCT
ajird-1393	39	8	we	we	PRON
ajird-1393	39	9	established	establish	VERB
ajird-1393	39	10	the	the	DET
ajird-1393	39	11	relationship	relationship	NOUN
ajird-1393	39	12	between	between	ADP
ajird-1393	39	13	g197a	g197a	PROPN
ajird-1393	39	14	polymorphism	polymorphism	NOUN
ajird-1393	39	15	of	of	ADP
ajird-1393	39	16	the	the	DET
ajird-1393	39	17	il	il	PROPN
ajird-1393	39	18	17a	17a	PROPN
ajird-1393	39	19	gene	gene	PROPN
ajird-1393	39	20	and	and	CCONJ
ajird-1393	39	21	the	the	DET
ajird-1393	39	22	presence	presence	NOUN
ajird-1393	39	23	of	of	ADP
ajird-1393	39	24	secukinumab	secukinumab	NOUN
ajird-1393	39	25	resistance	resistance	NOUN
ajird-1393	39	26	and	and	CCONJ
ajird-1393	39	27	disease	disease	NOUN
ajird-1393	39	28	activity	activity	NOUN
ajird-1393	39	29	.	.	PUNCT
ajird-1393	40	1	we	we	PRON
ajird-1393	40	2	identified	identify	VERB
ajird-1393	40	3	three	three	NUM
ajird-1393	40	4	groups	group	NOUN
ajird-1393	40	5	of	of	ADP
ajird-1393	40	6	respondents	respondent	NOUN
ajird-1393	40	7	for	for	ADP
ajird-1393	40	8	treatment	treatment	NOUN
ajird-1393	40	9	with	with	ADP
ajird-1393	40	10	this	this	DET
ajird-1393	40	11	drug	drug	NOUN
ajird-1393	40	12	.	.	PUNCT
ajird-1393	41	1	patients	patient	NOUN
ajird-1393	41	2	in	in	ADP
ajird-1393	41	3	the	the	DET
ajird-1393	41	4	“	"	PUNCT
ajird-1393	41	5	good	good	ADJ
ajird-1393	41	6	”	"	PUNCT
ajird-1393	41	7	response	response	NOUN
ajird-1393	41	8	phenotypic	phenotypic	NOUN
ajird-1393	41	9	group	group	NOUN
ajird-1393	41	10	,	,	PUNCT
ajird-1393	41	11	those	those	PRON
ajird-1393	41	12	with	with	ADP
ajird-1393	41	13	the	the	DET
ajird-1393	41	14	aa	aa	PROPN
ajird-1393	41	15	mutant	mutant	ADJ
ajird-1393	41	16	genotype	genotype	NOUN
ajird-1393	41	17	,	,	PUNCT
ajird-1393	41	18	showed	show	VERB
ajird-1393	41	19	a	a	DET
ajird-1393	41	20	good	good	ADJ
ajird-1393	41	21	clinical	clinical	ADJ
ajird-1393	41	22	response	response	NOUN
ajird-1393	41	23	to	to	PART
ajird-1393	41	24	secukinumab	secukinumab	VERB
ajird-1393	41	25	treatment	treatment	NOUN
ajird-1393	41	26	,	,	PUNCT
ajird-1393	41	27	as	as	ADV
ajird-1393	41	28	well	well	ADV
ajird-1393	41	29	as	as	ADP
ajird-1393	41	30	low	low	ADJ
ajird-1393	41	31	disease	disease	NOUN
ajird-1393	41	32	activity	activity	NOUN
ajird-1393	41	33	(	(	PUNCT
ajird-1393	41	34	das28	das28	PROPN
ajird-1393	41	35	<	<	X
ajird-1393	41	36	2.6	2.6	NUM
ajird-1393	41	37	)	)	PUNCT
ajird-1393	41	38	.	.	PUNCT
ajird-1393	42	1	patients	patient	NOUN
ajird-1393	42	2	in	in	ADP
ajird-1393	42	3	the	the	DET
ajird-1393	42	4	"	"	PUNCT
ajird-1393	42	5	poor	poor	ADJ
ajird-1393	42	6	"	"	PUNCT
ajird-1393	42	7	response	response	NOUN
ajird-1393	42	8	phenotypic	phenotypic	NOUN
ajird-1393	42	9	group	group	NOUN
ajird-1393	42	10	(	(	PUNCT
ajird-1393	42	11	patients	patient	NOUN
ajird-1393	42	12	with	with	ADP
ajird-1393	42	13	the	the	DET
ajird-1393	42	14	gg	gg	PROPN
ajird-1393	42	15	genotype	genotype	NOUN
ajird-1393	42	16	)	)	PUNCT
ajird-1393	42	17	were	be	AUX
ajird-1393	42	18	resistant	resistant	ADJ
ajird-1393	42	19	to	to	PART
ajird-1393	42	20	secukinumab	secukinumab	VERB
ajird-1393	42	21	,	,	PUNCT
ajird-1393	42	22	even	even	ADV
ajird-1393	42	23	with	with	SCONJ
ajird-1393	42	24	increasing	increase	VERB
ajird-1393	42	25	doses	dose	NOUN
ajird-1393	42	26	of	of	ADP
ajird-1393	42	27	the	the	DET
ajird-1393	42	28	drug	drug	NOUN
ajird-1393	42	29	,	,	PUNCT
ajird-1393	42	30	clinical	clinical	ADJ
ajird-1393	42	31	remission	remission	NOUN
ajird-1393	42	32	or	or	CCONJ
ajird-1393	42	33	low	low	ADJ
ajird-1393	42	34	disease	disease	NOUN
ajird-1393	42	35	activity	activity	NOUN
ajird-1393	42	36	(	(	PUNCT
ajird-1393	42	37	das28	das28	X
ajird-1393	42	38	>	>	X
ajird-1393	42	39	5.1	5.1	NUM
ajird-1393	42	40	)	)	PUNCT
ajird-1393	42	41	was	be	AUX
ajird-1393	42	42	not	not	PART
ajird-1393	42	43	achieved	achieve	VERB
ajird-1393	42	44	.	.	PUNCT
ajird-1393	43	1	patients	patient	NOUN
ajird-1393	43	2	in	in	ADP
ajird-1393	43	3	the	the	DET
ajird-1393	43	4	"	"	PUNCT
ajird-1393	43	5	moderate	moderate	ADJ
ajird-1393	43	6	"	"	PUNCT
ajird-1393	43	7	response	response	NOUN
ajird-1393	43	8	group	group	NOUN
ajird-1393	43	9	were	be	AUX
ajird-1393	43	10	carriers	carrier	NOUN
ajird-1393	43	11	of	of	ADP
ajird-1393	43	12	the	the	DET
ajird-1393	43	13	ga	ga	PROPN
ajird-1393	43	14	genotype	genotype	NOUN
ajird-1393	43	15	g197a	g197a	PROPN
ajird-1393	43	16	polymorphism	polymorphism	NOUN
ajird-1393	43	17	of	of	ADP
ajird-1393	43	18	the	the	DET
ajird-1393	43	19	il	il	PROPN
ajird-1393	43	20	17a	17a	PROPN
ajird-1393	43	21	gene	gene	PROPN
ajird-1393	43	22	,	,	PUNCT
ajird-1393	43	23	which	which	PRON
ajird-1393	43	24	showed	show	VERB
ajird-1393	43	25	a	a	DET
ajird-1393	43	26	moderate	moderate	ADJ
ajird-1393	43	27	drug	drug	NOUN
ajird-1393	43	28	response	response	NOUN
ajird-1393	43	29	to	to	PART
ajird-1393	43	30	secukinumab	secukinumab	VERB
ajird-1393	43	31	,	,	PUNCT
ajird-1393	43	32	and	and	CCONJ
ajird-1393	43	33	disease	disease	NOUN
ajird-1393	43	34	activity	activity	NOUN
ajird-1393	43	35	was	be	AUX
ajird-1393	43	36	moderate	moderate	ADJ
ajird-1393	43	37	(	(	PUNCT
ajird-1393	43	38	das28	das28	PROPN
ajird-1393	43	39	3.2	3.2	NUM
ajird-1393	43	40	-	-	SYM
ajird-1393	43	41	5.1	5.1	NUM
ajird-1393	43	42	)	)	PUNCT
ajird-1393	43	43	.	.	PUNCT
ajird-1393	44	1	conclusion	conclusion	NOUN
ajird-1393	44	2	:	:	PUNCT
ajird-1393	44	3	genetic	genetic	ADJ
ajird-1393	44	4	studies	study	NOUN
ajird-1393	44	5	of	of	ADP
ajird-1393	44	6	g197a	g197a	PROPN
ajird-1393	44	7	polymorphism	polymorphism	NOUN
ajird-1393	44	8	of	of	ADP
ajird-1393	44	9	the	the	DET
ajird-1393	44	10	il	il	PROPN
ajird-1393	44	11	17a	17a	PROPN
ajird-1393	44	12	gene	gene	VERB
ajird-1393	44	13	in	in	ADP
ajird-1393	44	14	patients	patient	NOUN
ajird-1393	44	15	with	with	ADP
ajird-1393	44	16	rea	rea	PROPN
ajird-1393	44	17	revealed	reveal	VERB
ajird-1393	44	18	their	their	PRON
ajird-1393	44	19	relationship	relationship	NOUN
ajird-1393	44	20	with	with	ADP
ajird-1393	44	21	resistance	resistance	NOUN
ajird-1393	44	22	to	to	ADP
ajird-1393	44	23	secukinumab	secukinumab	VERB
ajird-1393	44	24	,	,	PUNCT
ajird-1393	44	25	as	as	ADV
ajird-1393	44	26	well	well	ADV
ajird-1393	44	27	as	as	ADP
ajird-1393	44	28	disease	disease	NOUN
ajird-1393	44	29	activity	activity	NOUN
ajird-1393	44	30	during	during	ADP
ajird-1393	44	31	treatment	treatment	NOUN
ajird-1393	44	32	with	with	ADP
ajird-1393	44	33	this	this	DET
ajird-1393	44	34	drug	drug	NOUN
ajird-1393	44	35	.	.	PUNCT
ajird-1393	45	1	rea	rea	PROPN
ajird-1393	45	2	patients	patient	NOUN
ajird-1393	45	3	with	with	ADP
ajird-1393	45	4	the	the	DET
ajird-1393	45	5	gg	gg	NOUN
ajird-1393	45	6	genotype	genotype	NOUN
ajird-1393	45	7	have	have	VERB
ajird-1393	45	8	a	a	DET
ajird-1393	45	9	poor	poor	ADJ
ajird-1393	45	10	response	response	NOUN
ajird-1393	45	11	(	(	PUNCT
ajird-1393	45	12	resistance	resistance	NOUN
ajird-1393	45	13	)	)	PUNCT
ajird-1393	45	14	to	to	PART
ajird-1393	45	15	secukinumab	secukinumab	VERB
ajird-1393	45	16	treatment	treatment	NOUN
ajird-1393	45	17	,	,	PUNCT
ajird-1393	45	18	as	as	ADP
ajird-1393	45	19	a	a	DET
ajird-1393	45	20	result	result	NOUN
ajird-1393	45	21	,	,	PUNCT
ajird-1393	45	22	the	the	DET
ajird-1393	45	23	disease	disease	NOUN
ajird-1393	45	24	proceeds	proceed	VERB
ajird-1393	45	25	with	with	ADP
ajird-1393	45	26	a	a	DET
ajird-1393	45	27	high	high	ADJ
ajird-1393	45	28	degree	degree	NOUN
ajird-1393	45	29	of	of	ADP
ajird-1393	45	30	disease	disease	NOUN
ajird-1393	45	31	activity	activity	NOUN
ajird-1393	45	32	,	,	PUNCT
ajird-1393	45	33	compared	compare	VERB
ajird-1393	45	34	with	with	ADP
ajird-1393	45	35	patients	patient	NOUN
ajird-1393	45	36	with	with	ADP
ajird-1393	45	37	ga	ga	PROPN
ajird-1393	45	38	and	and	CCONJ
ajird-1393	45	39	aa	aa	PROPN
ajird-1393	45	40	genotypes	genotype	NOUN
ajird-1393	45	41	.	.	PUNCT
ajird-1393	46	1	patient	patient	ADJ
ajird-1393	46	2	genotyping	genotyping	NOUN
ajird-1393	46	3	can	can	AUX
ajird-1393	46	4	be	be	AUX
ajird-1393	46	5	used	use	VERB
ajird-1393	46	6	to	to	PART
ajird-1393	46	7	determine	determine	VERB
ajird-1393	46	8	the	the	DET
ajird-1393	46	9	effectiveness	effectiveness	NOUN
ajird-1393	46	10	of	of	ADP
ajird-1393	46	11	secukinumab	secukinumab	NOUN
ajird-1393	46	12	drug	drug	NOUN
ajird-1393	46	13	therapy	therapy	NOUN
ajird-1393	46	14	and	and	CCONJ
ajird-1393	46	15	personalized	personalized	ADJ
ajird-1393	46	16	selection	selection	NOUN
ajird-1393	46	17	of	of	ADP
ajird-1393	46	18	treatment	treatment	NOUN
ajird-1393	46	19	methods	method	NOUN
ajird-1393	46	20	for	for	ADP
ajird-1393	46	21	patients	patient	NOUN
ajird-1393	46	22	with	with	ADP
ajird-1393	46	23	rea	rea	PROPN
ajird-1393	46	24	.	.	PROPN
ajird-1393	46	25	references	reference	NOUN
ajird-1393	47	1	1	1	NUM
ajird-1393	47	2	.	.	PUNCT
ajird-1393	47	3	tanaka	tanaka	PROPN
ajird-1393	47	4	h	h	PROPN
ajird-1393	47	5	,	,	PUNCT
ajird-1393	47	6	arima	arima	PROPN
ajird-1393	47	7	y	y	PROPN
ajird-1393	47	8	,	,	PUNCT
ajird-1393	47	9	kamimura	kamimura	X
ajird-1393	47	10	d	d	X
ajird-1393	47	11	,	,	PUNCT
ajird-1393	47	12	tanaka	tanaka	PROPN
ajird-1393	47	13	y	y	PROPN
ajird-1393	47	14	,	,	PUNCT
ajird-1393	47	15	takahashi	takahashi	PROPN
ajird-1393	47	16	n	n	CCONJ
ajird-1393	47	17	,	,	PUNCT
ajird-1393	47	18	uehata	uehata	PROPN
ajird-1393	47	19	t	t	PROPN
ajird-1393	47	20	,	,	PUNCT
ajird-1393	47	21	maeda	maeda	PROPN
ajird-1393	47	22	k	k	PROPN
ajird-1393	47	23	,	,	PUNCT
ajird-1393	47	24	satoh	satoh	PROPN
ajird-1393	47	25	t	t	PROPN
ajird-1393	47	26	,	,	PUNCT
ajird-1393	47	27	murakami	murakami	PROPN
ajird-1393	47	28	m	m	PROPN
ajird-1393	47	29	,	,	PUNCT
ajird-1393	47	30	akira	akira	PROPN
ajird-1393	47	31	s.	s.	PROPN
ajird-1393	47	32	phosphorylation	phosphorylation	PROPN
ajird-1393	47	33	-	-	PUNCT
ajird-1393	47	34	dependent	dependent	ADJ
ajird-1393	47	35	regnase-1	regnase-1	NOUN
ajird-1393	47	36	release	release	NOUN
ajird-1393	47	37	from	from	ADP
ajird-1393	47	38	endoplasmic	endoplasmic	ADJ
ajird-1393	47	39	reticulum	reticulum	NOUN
ajird-1393	47	40	is	be	AUX
ajird-1393	47	41	critical	critical	ADJ
ajird-1393	47	42	in	in	ADP
ajird-1393	47	43	il-17	il-17	NUM
ajird-1393	47	44	response	response	NOUN
ajird-1393	47	45	.	.	PUNCT
ajird-1393	48	1	j	j	PROPN
ajird-1393	48	2	exp	exp	NOUN
ajird-1393	48	3	med	med	PROPN
ajird-1393	48	4	.	.	PROPN
ajird-1393	49	1	2019	2019	NUM
ajird-1393	49	2	jun	jun	PROPN
ajird-1393	49	3	3;216(6):1431	3;216(6):1431	NUM
ajird-1393	49	4	-	-	SYM
ajird-1393	49	5	1449	1449	NUM
ajird-1393	49	6	.	.	PUNCT
ajird-1393	50	1	2	2	NUM
ajird-1393	50	2	.	.	X
ajird-1393	50	3	khalmetova	khalmetova	PROPN
ajird-1393	50	4	f.	f.	PROPN
ajird-1393	50	5	i.	i.	PROPN
ajird-1393	50	6	,	,	PUNCT
ajird-1393	50	7	akhmedov	akhmedov	PROPN
ajird-1393	50	8	k.	k.	PROPN
ajird-1393	51	1	s.	s.	PROPN
ajird-1393	51	2	characteristics	characteristics	PROPN
ajird-1393	51	3	of	of	ADP
ajird-1393	51	4	articulate	articulate	ADJ
ajird-1393	51	5	syndrome	syndrome	NOUN
ajird-1393	51	6	in	in	ADP
ajird-1393	51	7	patients	patient	NOUN
ajird-1393	51	8	with	with	ADP
ajird-1393	51	9	reactive	reactive	ADJ
ajird-1393	51	10	arthritis	arthritis	NOUN
ajird-1393	51	11	.	.	PUNCT
ajird-1393	52	1	–	–	PUNCT
ajird-1393	52	2	2021	2021	NUM
ajird-1393	52	3	.	.	PUNCT
ajird-1393	53	1	3	3	X
ajird-1393	53	2	.	.	NUM
ajird-1393	53	3	abdurakhmanova	abdurakhmanova	PROPN
ajird-1393	53	4	n.	n.	PROPN
ajird-1393	53	5	,	,	PUNCT
ajird-1393	53	6	akhmedov	akhmedov	PROPN
ajird-1393	53	7	k.	k.	PROPN
ajird-1393	54	1	influence	influence	NOUN
ajird-1393	54	2	of	of	ADP
ajird-1393	54	3	polymorphism	polymorphism	NOUN
ajird-1393	54	4	c3435	c3435	PROPN
ajird-1393	54	5	t	t	PROPN
ajird-1393	54	6	mdr1	mdr1	PROPN
ajird-1393	54	7	gene	gene	NOUN
ajird-1393	54	8	to	to	PART
ajird-1393	54	9	methotrexate	methotrexate	VERB
ajird-1393	54	10	resistance	resistance	NOUN
ajird-1393	54	11	in	in	ADP
ajird-1393	54	12	patients	patient	NOUN
ajird-1393	54	13	with	with	ADP
ajird-1393	54	14	rheumatoid	rheumatoid	NOUN
ajird-1393	54	15	arthritis	arthritis	NOUN
ajird-1393	54	16	.	.	PUNCT
ajird-1393	55	1	–	–	PUNCT
ajird-1393	55	2	2019	2019	NUM
ajird-1393	55	3	.	.	PUNCT
ajird-1393	56	1	4	4	X
ajird-1393	56	2	.	.	X
ajird-1393	56	3	silva	silva	PROPN
ajird-1393	56	4	cendon	cendon	PROPN
ajird-1393	56	5	duran	duran	PROPN
ajird-1393	56	6	c	c	PROPN
ajird-1393	56	7	,	,	PUNCT
ajird-1393	56	8	barreto	barreto	PROPN
ajird-1393	56	9	santiago	santiago	PROPN
ajird-1393	56	10	m.	m.	PROPN
ajird-1393	56	11	cutaneous	cutaneous	ADJ
ajird-1393	56	12	vasculitis	vasculitis	PROPN
ajird-1393	56	13	during	during	ADP
ajird-1393	56	14	secukinumab	secukinumab	NOUN
ajird-1393	56	15	treatment	treatment	NOUN
ajird-1393	56	16	.	.	PUNCT
ajird-1393	57	1	ejcrim	ejcrim	VERB
ajird-1393	57	2	2020;7	2020;7	NOUN
ajird-1393	57	3	5	5	NUM
ajird-1393	57	4	.	.	PUNCT
ajird-1393	58	1	mirza	mirza	PROPN
ajird-1393	58	2	-	-	PUNCT
ajird-1393	58	3	bakhtiyarkhonovna	bakhtiyarkhonovna	PROPN
ajird-1393	58	4	,	,	PUNCT
ajird-1393	58	5	abdurakhmanova	abdurakhmanova	PROPN
ajird-1393	58	6	nargiza	nargiza	PROPN
ajird-1393	58	7	.	.	PUNCT
ajird-1393	59	1	"	"	PUNCT
ajird-1393	59	2	features	feature	NOUN
ajird-1393	59	3	of	of	ADP
ajird-1393	59	4	the	the	DET
ajird-1393	59	5	state	state	NOUN
ajird-1393	59	6	of	of	ADP
ajird-1393	59	7	the	the	DET
ajird-1393	59	8	cellular	cellular	ADJ
ajird-1393	59	9	and	and	CCONJ
ajird-1393	59	10	humoral	humoral	ADJ
ajird-1393	59	11	components	component	NOUN
ajird-1393	59	12	of	of	ADP
ajird-1393	59	13	immune	immune	ADJ
ajird-1393	59	14	system	system	NOUN
ajird-1393	59	15	in	in	ADP
ajird-1393	59	16	patients	patient	NOUN
ajird-1393	59	17	with	with	ADP
ajird-1393	59	18	ankylosing	ankylose	VERB
ajird-1393	59	19	american	american	ADJ
ajird-1393	59	20	journal	journal	PROPN
ajird-1393	59	21	of	of	ADP
ajird-1393	59	22	interdisciplinary	interdisciplinary	ADJ
ajird-1393	59	23	research	research	NOUN
ajird-1393	59	24	and	and	CCONJ
ajird-1393	59	25	development	development	NOUN
ajird-1393	59	26	issn	issn	PROPN
ajird-1393	59	27	online	online	NOUN
ajird-1393	59	28	:	:	PUNCT
ajird-1393	59	29	2771	2771	NUM
ajird-1393	59	30	-	-	SYM
ajird-1393	59	31	8948	8948	NUM
ajird-1393	59	32	website	website	NOUN
ajird-1393	59	33	:	:	PUNCT
ajird-1393	59	34	www.ajird.journalspark.org	www.ajird.journalspark.org	ADJ
ajird-1393	59	35	volume	volume	NOUN
ajird-1393	59	36	35	35	NUM
ajird-1393	59	37	,	,	PUNCT
ajird-1393	59	38	december	december	PROPN
ajird-1393	59	39	2024	2024	NUM
ajird-1393	59	40	63	63	NUM
ajird-1393	59	41	|	|	ADV
ajird-1393	59	42	p	p	NOUN
ajird-1393	59	43	a	a	DET
ajird-1393	59	44	g	g	NOUN
ajird-1393	59	45	e	e	NOUN
ajird-1393	59	46	spondyloarthritis	spondyloarthritis	NOUN
ajird-1393	59	47	after	after	ADP
ajird-1393	59	48	covid-19	covid-19	PROPN
ajird-1393	59	49	.	.	PUNCT
ajird-1393	59	50	"	"	PUNCT
ajird-1393	59	51	european	european	ADJ
ajird-1393	59	52	journal	journal	PROPN
ajird-1393	59	53	of	of	ADP
ajird-1393	59	54	molecular	molecular	ADJ
ajird-1393	59	55	&	&	CCONJ
ajird-1393	59	56	clinical	clinical	ADJ
ajird-1393	59	57	medicine	medicine	NOUN
ajird-1393	59	58	9.08	9.08	NUM
ajird-1393	59	59	:	:	SYM
ajird-1393	59	60	2022	2022	NUM
ajird-1393	59	61	.	.	PUNCT
ajird-1393	60	1	6	6	NUM
ajird-1393	60	2	.	.	X
ajird-1393	60	3	abdurakhmanova	abdurakhmanova	PROPN
ajird-1393	60	4	,	,	PUNCT
ajird-1393	60	5	n.	n.	NOUN
ajird-1393	60	6	,	,	PUNCT
ajird-1393	60	7	akhmedov	akhmedov	PROPN
ajird-1393	60	8	,	,	PUNCT
ajird-1393	60	9	k.	k.	PROPN
ajird-1393	60	10	,	,	PUNCT
ajird-1393	60	11	&	&	CCONJ
ajird-1393	60	12	rakhimov	rakhimov	PROPN
ajird-1393	60	13	,	,	PUNCT
ajird-1393	60	14	s.	s.	PROPN
ajird-1393	60	15	(	(	PUNCT
ajird-1393	60	16	2023	2023	NUM
ajird-1393	60	17	)	)	PUNCT
ajird-1393	60	18	.	.	PUNCT
ajird-1393	61	1	features	feature	NOUN
ajird-1393	61	2	of	of	ADP
ajird-1393	61	3	the	the	DET
ajird-1393	61	4	course	course	NOUN
ajird-1393	61	5	of	of	ADP
ajird-1393	61	6	rheumatoid	rheumatoid	VERB
ajird-1393	61	7	arthritis	arthritis	NOUN
ajird-1393	61	8	depending	depend	VERB
ajird-1393	61	9	on	on	ADP
ajird-1393	61	10	the	the	DET
ajird-1393	61	11	c3435	c3435	PROPN
ajird-1393	61	12	t	t	NOUN
ajird-1393	61	13	polymorphism	polymorphism	NOUN
ajird-1393	61	14	of	of	ADP
ajird-1393	61	15	the	the	DET
ajird-1393	61	16	mdr1	mdr1	PROPN
ajird-1393	61	17	gene	gene	NOUN
ajird-1393	61	18	.	.	PUNCT
ajird-1393	62	1	texas	texas	PROPN
ajird-1393	62	2	journal	journal	PROPN
ajird-1393	62	3	of	of	ADP
ajird-1393	62	4	multidisciplinary	multidisciplinary	ADJ
ajird-1393	62	5	studies	study	NOUN
ajird-1393	62	6	,	,	PUNCT
ajird-1393	62	7	21	21	NUM
ajird-1393	62	8	,	,	PUNCT
ajird-1393	62	9	18	18	NUM
ajird-1393	62	10	-	-	SYM
ajird-1393	62	11	24	24	NUM
ajird-1393	62	12	.	.	PUNCT
ajird-1393	63	1	7	7	X
ajird-1393	63	2	.	.	X
ajird-1393	63	3	akhmedov	akhmedov	PROPN
ajird-1393	63	4	,	,	PUNCT
ajird-1393	63	5	k.	k.	PROPN
ajird-1393	63	6	s.	s.	PROPN
ajird-1393	63	7	,	,	PUNCT
ajird-1393	63	8	rixsiyeva	rixsiyeva	PROPN
ajird-1393	63	9	,	,	PUNCT
ajird-1393	63	10	l.	l.	PROPN
ajird-1393	63	11	m.	m.	PROPN
ajird-1393	63	12	,	,	PUNCT
ajird-1393	63	13	abdurahmanova	abdurahmanova	PROPN
ajird-1393	63	14	,	,	PUNCT
ajird-1393	63	15	n.	n.	PROPN
ajird-1393	63	16	m.	m.	PROPN
ajird-1393	63	17	,	,	PUNCT
ajird-1393	63	18	botirbekov	botirbekov	PROPN
ajird-1393	63	19	,	,	PUNCT
ajird-1393	63	20	a.	a.	NOUN
ajird-1393	63	21	n.	n.	PROPN
ajird-1393	63	22	,	,	PUNCT
ajird-1393	63	23	turaev	turaev	PROPN
ajird-1393	63	24	,	,	PUNCT
ajird-1393	63	25	i.	i.	PROPN
ajird-1393	63	26	a.	a.	PROPN
ajird-1393	63	27	,	,	PUNCT
ajird-1393	63	28	&	&	CCONJ
ajird-1393	63	29	raximov	raximov	PROPN
ajird-1393	63	30	,	,	PUNCT
ajird-1393	63	31	s.	s.	PROPN
ajird-1393	63	32	s.	s.	PROPN
ajird-1393	63	33	(	(	PUNCT
ajird-1393	63	34	2023	2023	NUM
ajird-1393	63	35	)	)	PUNCT
ajird-1393	63	36	.	.	PUNCT
ajird-1393	64	1	changes	change	NOUN
ajird-1393	64	2	in	in	ADP
ajird-1393	64	3	c	c	NOUN
ajird-1393	64	4	-	-	PUNCT
ajird-1393	64	5	telopeptide	telopeptide	NOUN
ajird-1393	64	6	collagen	collagen	NOUN
ajird-1393	64	7	-	-	PUNCT
ajird-1393	64	8	ii	ii	NOUN
ajird-1393	64	9	level	level	NOUN
ajird-1393	64	10	in	in	ADP
ajird-1393	64	11	patients	patient	NOUN
ajird-1393	64	12	with	with	ADP
ajird-1393	64	13	ankylosing	ankylose	VERB
ajird-1393	64	14	spondyloarthritis	spondyloarthritis	NOUN
ajird-1393	64	15	after	after	ADP
ajird-1393	64	16	covid-19	covid-19	PROPN
ajird-1393	64	17	.	.	PROPN
ajird-1393	64	18	journal	journal	PROPN
ajird-1393	64	19	of	of	ADP
ajird-1393	64	20	modern	modern	ADJ
ajird-1393	64	21	educational	educational	ADJ
ajird-1393	64	22	achievements	achievement	NOUN
ajird-1393	64	23	,	,	PUNCT
ajird-1393	64	24	3(3	3(3	NUM
ajird-1393	64	25	)	)	PUNCT
ajird-1393	64	26	,	,	PUNCT
ajird-1393	64	27	78	78	NUM
ajird-1393	64	28	-	-	SYM
ajird-1393	64	29	87	87	NUM
ajird-1393	64	30	.	.	PUNCT